Outcome of in vitro fertilization in women with subclinical hypothyroidism.

Four thousand and seven hundred twenty subfertile women who underwent either classical IVF or IVF-Intracytoplasmic Sperm Injection (ICSI) were enrolled between January 2015 and March 2016 at the first people’s hospital of Yunnan Province PR China. The level of TSH was screened and the subjects with TSH level above 4.2 mIU/L were selected, serum levels of TSH, free triiodothyronine (FT3), free thyroxine (FT4) were measured. SCH is defined as an elevated TSH concentration (TSH 4.2-20 mIU/L) with normal serum levels of FT4. When SCH was confirmed, treatment with L-T4 was started and the target TSH level is within 0.2-4.2 mIU/l. After the approval of Institutional Review Board, we selected women aged 37 years or less who underwent their first fresh IVF retrieval cycle, using their own oocytes. Two hundred and seventy SCH women substituted with LT4 were considered for further study. They were eligible if serum TSH level was within 0.2-4.2mIU/L one month proceeding the IVF cycle. Age-matched euthyroid women who underwent either classical IVF or ICSI were selected as control group in the same period. This analysis exclusively refers to the first treatment cycle. During COH, participants were monitored closely with transvaginal ultrasound and serum hormone levels. When a lead follicle R18 mm in size was identified, intramuscular hCG was administered with oocyte retrieval 36 hours later. Three to 5 days after retrieval, embryo transfer (ET) was performed, and participants returned 14 days later for measuring serum hCG levels. Positive pregnancy test was defined as positive serum hCG, and participants were followed to determine pregnancy outcome (10 months). Samples were processed and serum stored at -20 °C for batched analysis. Exclusion criteria included those patients with ovarian hyperstimulation (E2 > 4000 pg/ml, the number of follicles over 20), poor ovarian response (less than three follicles after ovarian stimulating drugs), poor compliance. Clinical endpoints were rates of clinical pregnancy (gestational sac on ultrasound), miscarriage (loss after sonographic presence of gestational sac), and live birth (delivery confirmed via Society for Assisted Reproductive Technology and direct patient report). The levels of serum TSH, FT4, FT3 and thyroid peroxidase antibody (TPOAb) were measured with electro-chemiluminescence (ECL) immunoassays (CobasElesys 601, Roche). The TSH assay had a reference range of 0.27–4.2mIU/L with intra-assay coefficient of variation (CV) of 1.57–4.12%. For FT4, the reference range was 12-22pmol/L with intra-assay CV of 2.24%-6.33%. The FT3 reference range was 3.1-6.8pmol/L with intra-assay CV of 2.42%-5.63%. The TPOAb assay range was 5.0-1,000 IU/mL with intra-assay CV of 6.7%. Positive TPOAb status was >35 IU/mL.Positive pregnancy test was defined by serumβ-hCG more than 25mIU/ml, typically on day 12–14 after oocyte retrieval. Quantitative values were expressed as mean ± SD or as median and interquartile range, as appropriate. Wilcoxon Rank-Sum test (nonparametric analysis) was used for continuous data without a normal distribution; Chi-Square analysis was used for categorical data with large cell counts, the Fisher-Exact test analysis for categorical data with small cell counts, a p -value <0.05 was considered statistically significant.

We found in a cohort of 4720 subfertile women undergoing IVF that 5.8% of them had SCH. Two hundred and seventy SCH women were enrolled and substituted with L-T4. Ninety-four SCH women were excluded because their IVF cycle were cancelled, one hundred and seventy-six of 270 women (66.2%) completed all pregnancy study visits and included in the final analysis. Of the 4407 women (93.3%) with normal thyroid screen results, 200 were eligible and participated in the study. Baseline characteristics of the levothyroxine treated SCH group and the euthyroid group were similar. The frequencies of adverse pregnancy outcomes did not differ significantly between the two study groups (Table  1 ). Eighty-two of 176 (46.6%) L-T4 treated SCH women who underwent ET had positive pregnancy tests. Seventy-eight of 176 (44.31%) became clinically pregnant. Eight pregnancies (10.3%) resulted in miscarriages (before 12 weeks of gestation). Overall rates of clinical pregnancy (44.31% vs 38.36%, P  = .251) and miscarriage (10.3% vs 10.7%, P  = .39) were not significantly different between L-T4 treated SCH women and euthyroid women who underwent IVF in the same period. Table 1 Baseline characteristics and IVF outcomes in Treated SCH and Euthyroid Patients Sub-hypo women Euthyroid women P Number of patients n  = 176 n  = 200 Age (yrs) 29.89 ± 4.07 30.45 ± 4.21 0.056 BMI(kg/m2) 22.76 ± 3.54 22.41 ± 2.89 0.099 TSH range(mIU/L) 0.32,4.21 0.57,4.21 0.420 Indication to IVF 0.439 Tubal factor infertility 50% 54.3% Ovulatory dysfunction 7.95% 5.9% 0.059 Endometriosis 2.2% 1.4% Male 15.9% 16.2% Mixed 21.6% 20% Unexplained infertility 6.5% 6.7% Clinical pregnancies 44.31% 38.36% 0.251 Miscarriages 10.3% 10.7% 0.39 Baseline characteristics and IVF outcomes in Treated SCH and Euthyroid Patients One hundred and fourteen of 176 L-T4 treated SCH women (64.8%) had a TSH level within 0.2-2.5mIU/L before the IVF cycle. Fifty-four (47.4%) of them had positive pregnancy tests and all of them had clinical pregnancies. Fifty (43.9%) had a live birth and four (7.4%) pregnancy resulted in miscarriage. Of the remaining 62 participants with a TSH level within 2.5–4.2mIU/L before the IVF cycle, 28 (45.2%) of them had positive pregnancy tests but only 24 (38.7%) became clinically pregnant, 20 (32.3%) had a live birth, 4 (16.7%) resulting in miscarriages. The rates of clinical pregnancy ( P  = .436), miscarriages ( P  = .379) and live birth ( P  = .288) were similar between two groups. In addition, total number of oocytes retrieved ( P  = .752), good quality embryos ( P  = .752) were similar between these two groups. The baseline characteristics and cycle outcome of women whose serum TSH did and did not exceed the threshold of 2.5 mIU/L before the IVF cycle are shown in Table  2 . No statistically significant differences were observed. An intragroup analysis according to thyroid autoimmunity detected also failed to document any significant result (data not shown). Table 2 Baseline characteristics and IVF outcomes in women serum TSH concentration did and did not exceed 2.5 mIU/L before the IVF cycle Characteristics TSH ≥ 2.5mIU/L TSH < 2.5mIU/L P n  = 62 n  = 114 Age (yrs) 30.48 ± 4.07 29.56 ± 4.37 0.336 BMI(kg/m2) 23.60 ± 4.05 22.29 ± 3.18 0.099 Previous pregnancies 48.4% 54.4% AFC 12.00 ± 5.00 12.00 ± 8.00 0.972 TSH(mIU/L) 2.60,4.21 0.32,1.88 0.0 FT3(pmol/L) 4.73 ± 0.76 5.10 ± 0.99 0.005 FT4(pmol/L) 17.29 ± 2.29 20.10 ± 3.99 0.001 Indication to IVF 0.439 Tubal factor infertility 45.2% 52.6% Ovulatory dysfunction 6.4% 8.8% Endometriosis 3.2% 0% Male 12.9% 17.5% Mixed 25.8% 19.3% Unexplained infertility 6.5% 1.8% Protocol of stimulation Long protocol 77.4% 89.5% Short protocol 6.5% 3.5% GnRH antagonists 3.2% 0% ART procedure 0.8 IVF 75.8% 70.2% ICSI 24.2% 29.8% Duration of stimulation(Days) 11.23 ± 1.82 11.98 ± 2.09 0.106 Total amount of recombinant FSH administration 2025 ± 825 2475.00 ± 1350.00 0.128 Serum estradiol at HCG Administration(pg/ml) 1983.50 ± 2079 2529.00 ± 2005.00 0.108 Total number of oocytes retrieved 10.00 ± 8.00 11.00 ± 8.00 0.752 Total number of good quality embryos 2.00 ± 3.00 4.00 ± 6.00 0.767 Clinical pregnancies 38.7% 47.4% 0.436 Miscarriages 16.7% 7.4% 0.379 Live birth rate 32.3% 43.9% 0.288 Data are reported as %,mean ± standard deviation or quartile,as appropriate AFC antral follicle, BMI , body mass index, FSH follicle-stimulating hormone, GnRH gonadotropin-releasing hormone Baseline characteristics and IVF outcomes in women serum TSH concentration did and did not exceed 2.5 mIU/L before the IVF cycle Data are reported as %,mean ± standard deviation or quartile,as appropriate AFC antral follicle, BMI , body mass index, FSH follicle-stimulating hormone, GnRH gonadotropin-releasing hormone Subgroup analyses were performed within the group of women with treated SCH. We compared women with ( n  = 102) and without ( n  = 74) thyroid autoimmunity. The median serum TSH before the IVF cycle was 1.81 (0.95–3.69) and 1.71 (0.95–2.69) mIU/L, respectively ( p  = 0.22). Baseline characteristics of the two study groups were similar with the exception of total amount of recombinant FSH, which was slightly higher in women without thyroid autoimmunity (1950.0 ± 1650.0 vs. 2400.0 ± 1950.0 IU, p  = 0.031). The main findings of the IVF outcomes are summarized in Table  3 . No statistically significant differences emerged. Table 3 Baseline characteristics and IVF outcomes in women with treated subclinical hypothyroidism with or without thyroid antibodies Characteristics AB POS AB NEG P n  = 102 n  = 74 Protocol of stimulation Long protocol 88.3% 97.3% Short protocol 3.9% 2.7% GnRH antagonists 7.8% 0% ART procedure 0.241 IVF 70.6% 81.1% ICSI 29.4% 18.9% Duration of stimulation(Days) 11.0 ± 10.0 12.0 ± 10.25 0.204 Total amount of recombinant FSH administration 1950.0 ± 1650.0 2400.0 ± 1950.0 0.031 Serum estradiol at HCG Administration(pg/ml) 2566.36 ± 1162.43 2269.04 ± 1239.37 0.34 Total number of oocytes retrieved 10.00 ± 6.00 11.00 ± 7.25 0.922 Total number of good quality embryos 2.00 ± 1.00 3.00 ± 1.00 0.965 Clinical pregnancies 47.1% 40.6% 0.566 Miscarriages 9.0% 18.2% 0.602 Live birth rate 43.1% 34.4% 0.291 Baseline characteristics and IVF outcomes in women with treated subclinical hypothyroidism with or without thyroid antibodies

Subclinical hypothyroidism (SCH) is a common mild thyroid disorder in women of childbearing age and may contribute to increased risk of infertility and adverse obstetric outcome of pregnancy. Observational studies examined the effect of SCH on pregnancy related outcomes, and it has been associated with multiple adverse outcomes in many, but not all, studies [ 1 ]. A recent multicenter, randomized, placebo-controlled trial found that pregnant women with treated SCH whose median TSH was 4.2 mIU/l are at the same frequencies for pregnancy loss, placental abruption, premature rupture of membranes, and neonatal death compared with untreated women [ 2 ]. Although unsound evidence exists,several professional organizations have maintained to recommend routine prenatal screening for and treatment of SCH during pregnancy [ 3 , 4 ]. The alteration of serum estrogen level during pregnancy has a profound physiological impact on thyroid function. Production of thyroid hormone increases by approximately 50% during pregnancy as a normal physiological response [ 5 ]. The functional reserve of thyroid is poor in hypothyroid women substituted with levothyroxine (L-T4) and they need to increase dose of medication to maintain normal thyroid function during pregnancy. Controlled ovarian stimulation (COH) is a standard component of in vitro fertilization (IVF), which is able to induce a supra-physiological maternal serum estradiol level and may have a greater effect on thyroid function than natural conception [ 6 , 7 ]. Several investigations showed that IVF had an effect on serum TSH level in L-T4 treated hypothyroid women [ 8 ]. Moreover,the majority of evidence shows that SCH has a negative effect on outcome of IVF [ 9 ]. However, whether this negative influence may be attenuated with L-T4 treatment, the benefits of strictly controlled TSH level before IVF are still unknown [ 3 , 9 ]. Our aim was to investigate the rate of pregnancies of IVF in SCH women substituted with L-T4 and evaluate whether TSH less than 2.5 mIU/l is the optimal cut-off point before IVF cycle. We performed a prospective cohort study with patients undergoing their first IVF retrieval cycle at a single cite from January 2015 to March 2016 (15 months).

In conclusion, our results suggest that L-T4 treatment in women with SCH requiring IVF had similar rates of pregnancy and adverse pregnancy outcomes compared to euthyroid women. Strictly controlled TSH (less than 2.5 mIU/L) before IVF may have no effect on the pregnancy rate and maternal adverse pregnancy results. Whether the risk of other adverse outcomes could be attenuated calls for further studies to evaluate the effectiveness of thyroid hormone treatment in this population.

Using the definition of TSH level greater than the upper limit of normal range (4-5mIU/L) with normal FT4 levels, the incidence of SCH has been reported approximately 4–8% in reproductive age population [ 10 , 11 ]. Similarly, the incidence of SCH during pregnancy ranged from 2 to 2.5% [ 3 ]. Some investigators reported that SCH is more prevalent in infertile women [ 12 , 13 ]. In a retrospective study, an elevated serum TSH was found in 4% of 335 infertile Finnish women with unknown history of thyroid dysfunction [ 8 ]. The incidence was highest in those with ovulatory dysfunction (6%) and unexplained infertility [ 5 ]. In this study, we enrolled 4720 subfertile women who underwent IVF for thyroid function examination. The incidence of SCH was 5.8%, using an upper cutoff TSH level of 4.2mIU/l, which is consistent with previous investigations [ 12 , 13 ]. Multiple studies have reported an association of SCH with an increased risk of adverse pregnancy outcomes including placental abruption, preterm birth, fetal death, and preterm premature rupture of membranes (PPROM) [ 3 , 14 ], but not all. There is fair evidence that SCH, defined as TSH outside of the normal reference range in pregnancy, is associated with miscarriage [ 3 , 15 ]. Untreated SCH affected the pregnancy outcomes in women requiring IVF, such as decreased pregnancy rate, implantation rate and delivery rate. Current data have demonstrated some benefits of L-T4 treatment in reducing these events [ 9 ]. In 2007, investigators performed a randomized trial on a population of 70 infertile patients with SCH who had undergone IVF. Patients were randomly assigned to either the L-T4 treatment group (50–100 mc g L-T4 starting at one month before the assisted reproduction technology procedure) or the placebo group. They found that compared with untreated group, the miscarriage rate was significantly lower (9% vs 13%, respectively) and the clinical pregnancy rate and delivery rate were significantly higher (35% and 10% vs 26% and 3%, respectively) in L-T4 treatment group[ 16 ]. Another study randomized 64 women with SCH to the L-T4 treatment group (50 mcg L-T4 starting at day 1 of ovarian stimulation) or the control group [ 17 ]. They observed a significant increase in the number of grade I or II embryos ( P  = .007) and in the implantation rate (26.9% vs 14.9%, P  = .044). The miscarriage rate was significantly lower in the L-T4 treatment group (0 vs 33.3%; P  = .021) and as a result, the live-birth rate was significantly higher in the L-T4 treatment group (53.1% vs 25%, P  = .039). In our study, 176 SCH women were substituted with L-T4 and their TSH levels were maintained within 0.2-4.2 mIU/L one month before the IVF cycle. We found that the rate of positive pregnancy test, clinical pregnancies and miscarriage were similar between treated SCH women and euthyroid women who underwent IVF, which is consistent with previous investigations. The investigation found that IVF outcome was not significantly hampered in women with adequately treated hypothyroidism [ 18 ]. There is powerful evidence that L-T4 treatment in women with SCH is associated with improvement in pregnancy and miscarriage rates [ 1 ], but, the benefit of thyroid hormone use on pregnancy loss was maily observed among women with basal TSH concentrations of 4.1–10.0 mIU/L, not those with concentrations of 2.5-4.0 mIU/L. Furthermore, the benefits of strict TSH control remains to be determined [ 4 , 19 – 21 ]. Few studies have examined if the risks of adverse obstetric outcomes are increased with a TSH level higher than 2.5mIU/L but less than the upper range of normal at the time of conception in IVF. Although unsound evidence exists recent Clinical Practice Guideline by The Endocrine Society suggests TSH levels in subclinical women should be less than 2.5 mIU/L before pregnancy, particularly in women requiring IVF [ 4 ]. One study measured 1231 women pursuing assisted reproductive technologies (ART). In this study, investigators found no evidence of an elevated pregnancy loss rate in women with preconception elevated TSH (2.5–4.0 mIU/L) [ 22 ]. The observation is in agreement with a recent study by Reh et al. who found no difference in clinical pregnancy, delivery, or miscarriage in patients with mildly elevated basal TSH (>2.5 and 0.4 to <2.5 mIU/L) [ 20 ]. Other studies suggest that there is a trend toward increasing risk of miscarriage with increasing TSH level, although this trend did not reach statistical significance [ 21 ]. These controversal results raise questions about the current guideline recommended threshold of 2.5 mIU/L for treating SCH when thyroid antibody was positive. In our study, no differences in the rates of positive pregnancy test, clinical pregnancies, miscarriage or live birth were observed in treated SCH women with different TSH level. There was no significant difference between the two groups with the number of oocytes retrieved and in the implantation rate. In addition, we also use TSH values greater than 2.5 mIU/L on HCG admistration day as a cut-off point. There were no differences in the rates of positive pregnancy test, clinical pregnancies, miscarriage or live birth in different groups (data not shown). However, due to the small sample size, the statistical power of this study was limited. In addition, since we didn’t adjust the levothyroxine dose during COH, we cannot determine whether there is an association between TSH alteration during ART and IVF outcome. We didn’t measure urinary iodine in this study that was also a flaw. Finally, according to ATA guideline, we arbitrarily chose 2.5 mIU/L as a strictly controlled TSH threshold. It would have been more appropriate to refer to a local threshold since reference range may vary among different ethnics and is not always correct to use the same threshold for all ethnics.